Advanced search
Publication Cover
European Clinical Respiratory Journal Volume 3, 2016 - Issue 1
Submit an article Journal homepage
1,071
Views
35
CrossRef citations to date
0
Altmetric
Original Research Articles

Idiopathic pulmonary fibrosis in Sweden: report from the first year of activity of the Swedish IPF-Registry

Giovanni FerraraDepartment of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden;Respiratory Medicine Unit, Department of Medicine, Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, SwedenCorrespondence[email protected]
,
Lisa CarlsonDepartment of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden
,
Andreas PalmGävle Hospital, Gävle, Sweden
,
Jonas EinarssonSkåne University Hospital, Malmö, Sweden;Department of Respiratory Medicine and Allergology, Skåne University Hospital, Lund University, Lund, Sweden
,
Cecilia OlivestenSunderby Hospital, Luleå, Sweden
,
Magnus SköldDepartment of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden;Respiratory Medicine Unit, Department of Medicine, Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
&
for the Swedish Idiopathic Pulmonary Fibrosis Registry Group
 show all
Article: 31090 | Received 23 Jan 2016, Accepted 29 Mar 2016, Published online: 21 Apr 2016

References

  • Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, etal. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183: 788–824. [PubMed Abstract].
  • Thomeer M, Demedts M, Behr J, Buhl R, Costabel U, Flower CDR, etal. Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. Eur Respir J. 2008; 31: 585–91. [PubMed Abstract].
  • Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006; 174: 810–6. [PubMed Abstract].
  • Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994; 150: 967–72. [PubMed Abstract].
  • Gribbin J, Hubbard RB, Le Jeune I, Smith CJP, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006; 61: 980–5. [PubMed Abstract] [PubMed CentralFull Text].
  • Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax. 2002; 57: 338–42. [PubMed Abstract] [PubMed CentralFull Text].
  • Svensk Lungmedicinsk Föräning. Vårdprogram för idiopatisk lungfibros [Internet]. 2012; Svensk Lungmedicinsk föräning. Available from: http://www.slmf.se/sites/default/files/VPIL_2013_web_final.pdf [cited 19 January 2016].
  • King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, etal. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370: 2083–92. [PubMed Abstract].
  • Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, etal. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377: 1760–9. [PubMed Abstract].
  • Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, etal. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011; 365: 1079–87. [PubMed Abstract].
  • Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, etal. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370: 2071–82. [PubMed Abstract].
  • Tandvårds och Läkemedelsförmånsverket. Underlag för beslut om subvention – Esbriet (pirfenidon). Available from: http://www.tlv.se/Upload/Beslut_2015/underlag-beslut-esbriet.pdf [cited 19 January 2016].
  • Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, etal. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012; 185: 1044–8. [PubMed Abstract].
  • Patel AS, Siegert RJ, Brignall K, Gordon P, Steer S, Desai SR, etal. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax. 2012; 67: 804–10. [PubMed Abstract].
  • National Cancer Institute. Common terminology criteria for adverse events. US National Institutes of Health: National Cancer Institute. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40 [cited 19 January 2016]..
  • Wapenaar M, Patel AS, Birring SS, van Domburg R, Bakker E, Sköld M, etal. The King's Brief Interstitial Lung Disease (K-BILD) questionnaire: the development of Dutch, French, Italian and Swedish versions.
  • Ferrara G, Andersson O, Sköld M. Ett svenskt kvalitetsregister för idiopatisk lungfibros (IPF). Lung Allergi Forum. 2014; 4: 67.
  • Ferrara G, Carlsson L, Sköld M. Det nationella Lungfibrosregistret: framsteg och implementering. Lung Allergi Forum. 2015; 4: 53.
  • Sköld M, Ferrara G, Carlson L. Register lanserat för idiopatisk lungfibros. Lung Allergi Forum. 2014; 4: 59–61.
  • Carlson L, Ferrara G. Lungfibrosregistret, ett år!. Lung Allergi Forum. 2015; 3: 39.
  • Ferrara G, Carlson L. Nytt register gynnar patienter med lungfibros. Dagens Medicin. 2015; 22: 1.
  • Lungfibrosregistret. Available from: http://www.slmf.se/lungfibrosregistret [cited 19 May 2015]..
  • Moodley Y, Goh N, Glaspole I, Macansh S, Walters EH, Chapman S, etal. Australian Idiopathic Pulmonary Fibrosis Registry: vital lessons from a national prospective collaborative project. Respirology. 2014; 19: 1088–91. [PubMed Abstract].
  • Fernández Pérez ER, Daniels CE, Schroeder DR, St Sauver J, Hartman TE, Bartholmai BJ, etal. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest. 2010; 137: 129–37.
  • Kaunisto J, Kelloniemi K, Sutinen E, Hodgson U, Piilonen A, Kaarteenaho R, etal. Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis. BMC Pulm Med. 2015; 15: 92. [PubMed Abstract] [PubMed CentralFull Text].
  • Glaspole I, Goh N, Hopkins P, Moodley Y, Reynolds PN, Walters EH, etal. Quality of life of patients with idiopathic pulmonary fibrosis (IPF): what can the Australian IPF registry tell us?. Amsterdam, Netherlands: ERS. OA4964.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.